1. Home
  2. Directory
  3. Iowa
  4. Des Moines
  5. Physician Assistant
  6. NPI Profile
  7. Prescriptions 1497382949

SARAH LOCHMAN PA
Prescription History 1497382949
Physician Assistant - Medical in Des Moines, IA

NPI Status: Active since March 25, 2020

Contact Information

3200 GRAND AVE
DES MOINES, IA
ZIP 50312
Phone: (515) 271-1569

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SARAH LOCHMAN PA, an active Medical specialist practicing in Des Moines, IA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 77 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 17 claims alone.

Medication Index

Gabapentin

Generic Formulation: GabapentinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 13
30-Day Fills 18.0
Days Supply 540
IA State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills147.3
Peer Average Days Supply4,286
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.0% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $182.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.03

State Avg Cost Per Claim

$26.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 250
IA State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills63.0
Peer Average Days Supply1,102
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.3% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $353.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.10

State Avg Cost Per Claim

$21.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 13
30-Day Fills 28.4
Days Supply 848
IA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills65.7
Peer Average Days Supply1,934
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $367.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.23

State Avg Cost Per Claim

$27.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply779
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.7% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,365.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$760.52

State Avg Cost Per Claim

$1,828.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.7
Peer Average Days Supply849
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.6% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $136,257.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,354.83

State Avg Cost Per Claim

$13,965.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Letrozole

Generic Formulation: LetrozoleSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 17
30-Day Fills 31.0
Days Supply 930
IA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills115.4
Peer Average Days Supply3,441
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.5% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $510.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.03

State Avg Cost Per Claim

$21.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SARAH LOCHMAN PA provides transparency into local medical care patterns within Des Moines, IA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.